Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$16 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-86.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
13.1
Industry P/E
61.46
EV/EBITDA
-8.7
Div. Yield
0 %
Debt to Equity
2
Book Value
$--
EPS
$-0.5
Face value
--
Shares outstanding
23,559,800
CFO
$-14.29 Mln
EBITDA
$-61.63 Mln
Net Profit
$-83.12 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PetVivo Holdings Inc (PETV)
| 29.0 | 8.7 | 53.8 | -- | -26.9 | -15.4 | -27.2 |
|
BSE Sensex
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
PetVivo Holdings Inc (PETV)
| -41.3 | -45.9 | -48.0 | -71.5 | 578.8 | -12.1 | -70.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PetVivo Holdings Inc (PETV)
|
0.8 | 16.4 | 1.0 | -8.6 | -395.1 | -- | -- | 13.1 |
| 13.3 | 9,247.0 | 6,685.2 | 715.6 | 16.4 | 12.3 | 13 | 1.5 | |
| 250.1 | 6,628.2 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 232.6 | 6,325.6 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 0.9 | |
| 97.8 | 5,722.6 | 404.5 | -123.7 | -26.1 | -17.3 | -- | 7.5 | |
| 57.5 | 7,834.4 | 2,510.8 | 185.6 | 8.8 | 4.5 | 43.2 | 1.9 | |
| 71.8 | 8,997.9 | 12,669.0 | 407.0 | 5.4 | 11.8 | 22.4 | 2.7 | |
| 166.0 | 8,955.9 | 1,973.6 | -494.5 | -11.4 | -41 | -- | 9.3 | |
| 252.4 | 9,952.9 | 1,240.1 | 42.2 | 4.1 | 3.6 | 238 | 8.2 | |
| 117.8 | 6,677.4 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.6 |
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of... lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota. Read more
CEO, President & Director
Mr. John Lai
CEO, President & Director
Mr. John Lai
Headquarters
Edina, MN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of PetVivo Holdings Inc (PETV) stood at $ 6 Mln as on 31-Dec-24
The share price of PetVivo Holdings Inc (PETV) is $0.80 (NASDAQ) as of 23-Jun-2025 13:34 EDT. PetVivo Holdings Inc (PETV) has given a return of -26.94% in the last 3 years.
PetVivo Holdings Inc (PETV) has a market capitalisation of $ 16 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of PetVivo Holdings Inc (PETV) is 13.10 times as on 20-Jun-2025, a 272% premium to its peers’ median range of 3.52 times.
Since, TTM earnings of PetVivo Holdings Inc (PETV) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the PetVivo Holdings Inc (PETV) and enter the required number of quantities and click on buy to purchase the shares of PetVivo Holdings Inc (PETV).
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota.
The CEO & director of Mr. John Lai. is PetVivo Holdings Inc (PETV), and CFO & Sr. VP is Mr. John Lai.
There is no promoter pledging in PetVivo Holdings Inc (PETV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
995
|
|
|
906
|
|
|
889
|
|
|
883
|
|
|
777
|
|
|
708
|
|
|
663
|
|
|
663
|
|
|
585
|
| PetVivo Holdings Inc (PETV) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-395.07
|
|
Net Margin(%)
|
-902.7
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of PetVivo Holdings Inc (PETV) was $0 Mln.
